stockrow
Saturday 7 November 2026
Export IPSC’s income statement to Excel — free account
Century Therapeutics, Inc.
IPSC Healthcare Biotechnology
Century Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $109.2 million, up 1,556.8% from fiscal 2024.
- Revenue
- +12,667.7%
- EPS
- +55.3%
- Free cash flow
- +26.7%
Quarter to June 2026, against a year earlier
1.68
0.17
+11.26%
Follow IPSC
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
6.03 | 5.79 | 9.94 | 7.94 | |
Current Ratio |
6.25 | 5.97 | 10.25 | 8.28 | |
Net Debt/EBITDA |
3.96 | 6.71 | 6.45 | 3.51 | |
Debt/Assets |
0.01% | 0.01% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.74 | 0.84 | 1.17 | 0.57 | |
Capex/Depreciation |
(0.07) | 0.04 | (0.21) | (0.26) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.14 | 0.15 | 0.10 | 0.12 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.30) | (0.19) | (0.13) | (0.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.30) | (0.18) | (0.13) | (0.10) | |
Cash per Share |
1.54 | 1.35 | 0.70 | 0.58 | |
Shareholders Equity per Share |
2.04 | 1.84 | 1.37 | 1.13 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.04 | 1.84 | 1.37 | 1.13 | |
Free Cash Flow |
(25.78) | (15.94) | (25.85) | (20.47) | |
Working Capital |
115.68 | 100.54 | 125.47 | 109.70 | |
Capital Expenditures |
(0.19) | 0.14 | (0.58) | (0.63) | |
Net Current Asset Value |
69.34 | 56.00 | 77.23 | 70.11 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
2.61 | 3.92 | 3.36 | 4.02 | |
Average Assets |
316.67 | 288.46 | 321.08 | 285.85 | |
Average Common Equity |
186.02 | 160.15 | 252.59 | 221.12 |
Columns are period end dates · fundamentals updated 25 Oct 2026